Franklin Genomic Advancements ETF
$41.65−0.65 (−1.54%)
- 0.50%
- $30M
- +31.8%
- 0.34%
- 0M sh
- $42.30
- low $31.24high $45.58
The ETF.net HELX Grade
D
Score 38 out of 100
- 14 of 17
Score 38 of 100 falls in the D band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.
Cost
The fund’s net expense ratio, ranked against its category.D38 out of 100Rank 10 of 17Mission
Whether the fund did what it promised, tested against its stated mandate.Risk
How the fund held up when markets fell: downside volatility, drawdowns and tail loss.C40 out of 100Rank 11 of 17Tradability
How easy the fund is to trade: daily volume, and how far its price strays from net asset value.D34 out of 100Rank 12 of 17Holdings
How concentrated the fund is, and how complete and current its disclosed holdings are.C48 out of 100Rank 11 of 17Durability
Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.C41 out of 100Rank 12 of 17
Our read on HELX
DMost genomics funds hand you an index. Franklin's take is a stock-picker's portfolio of roughly 60 global names tied to gene sequencing, gene therapy and precision medicine, launched in 2020 with a plain mandate: capital appreciation.
The Fund seeks capital appreciation.
Why people hold it
- A concentrated bet, not a basket: about 60 global holdings across the genomics chain, so individual breakthroughs actually move the fund instead of being diluted by hundreds of names.
- Global by design. The mandate is not fenced to US listings, which matters in a field where sequencing and gene-therapy leaders sit in Europe and Asia too.
- Fee sits right at the middle of the genomics and biotech peer group at 0.50%, so you are not paying a premium over the typical thematic competitor for a discretionary approach.
- Live since 2020, giving it a multi-year record through a brutal stretch for biotech, rather than a launch-window track record.
Worth knowing
- It is a small, thinly traded fund. Use limit orders, expect wider spreads than the big index names, and know that small ETFs carry more closure risk than entrenched ones.
- The low-cost, high-liquidity lane in this category belongs to index products like IBBQ (0.19%) and IBB (0.44%). HELX's case rests on the manager's picks, not on price or trading ease.
- Genomics is a growth-style, high-volatility corner of health care. Clinical trial results and rate moves can swing a 60-stock portfolio hard in both directions.
HELX Holdings
- Stocks
- 68
- 50%
- NTRA
Sectors
- Health Care97.0%
- Materials2.3%
- Technology0.7%
Geography
- United States90.13%
- Germany2.05%
- United Kingdom1.94%
- Netherlands1.87%
- Ireland1.29%
- Switzerland1.17%
- South Korea0.95%
- Denmark0.59%
HELX Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Not enough history yet.
HELX$13,180
Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | HELX |
|---|---|
| Year to date | +16.5% |
| 1 month | +3.2% |
| 3 months | +5.3% |
| 1 year | +31.8% |
| 3 years | +15.2% |
| 5 years | −2.8% |
| 10 years | — |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | HELX |
|---|---|---|
| 2026 YTD | +16.5% | |
| 2025 | +26.4% | |
| 2024 | −5.3% | |
| 2023 | +1.1% | |
| 2022 | −37.9% | |
| 2021 | +9.8% | |
| 2020 | +85.1% |
HELX in the news
HELX Dividends
- 0.34%
- $0.14
- $0.14 per share
- Irregular
Distribution history
HELX Risk
- 21.9%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.60
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −55.4%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.96
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
HELX Cost
0.50%
HELX0.50%
- The middle half of Biotech & Genomics funds
- Median 0.47%
9 of the 17 Biotech & Genomics funds charge less.
Other funds in Biotech & Genomics
- CGNOMGlobal X - Genomics & Biotechnology ETFExpense ratio 0.50%1 year return +64.9%
- CWDNAWisdomTree BioRevolution FundExpense ratio 0.45%1 year return +41.9%
- DARKGARK Genomic Revolution ETFExpense ratio 0.75%1 year return +63.0%
- DBBCVirtus Biotech Clinical Trials ETFExpense ratio 0.65%1 year return +51.2%
- DCANCTema Oncology ETFExpense ratio 0.99%1 year return +37.4%